Indraprastha Medical Corporation Limited
Indraprastha Medical Corporation Limited (INDRAMEDCO.NS) Stock Competitors & Peer Comparison
See (INDRAMEDCO.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INDRAMEDCO.NS | ₹399.70 | +7.35% | 36.6B | 20.03 | ₹19.96 | +1.21% |
| APOLLOHOSP.NS | ₹7,305.50 | -1.53% | 1.1T | 58.30 | ₹125.31 | +0.26% |
| APOLLOHOSP.BO | ₹7,305.00 | -1.66% | 1.1T | 58.30 | ₹125.30 | +0.26% |
| MAXHEALTH.NS | ₹958.90 | -0.35% | 933.1B | 65.99 | ₹14.53 | +0.16% |
| MAXHEALTH.BO | ₹958.15 | -0.36% | 932.4B | 65.99 | ₹14.52 | +0.16% |
| FORTIS.NS | ₹795.00 | +0.00% | 600.2B | 62.50 | ₹12.72 | +0.13% |
| FORTIS.BO | ₹794.55 | -0.01% | 599.9B | 62.51 | ₹12.71 | +0.13% |
| ASTERDM.BO | ₹687.95 | +2.44% | 355.6B | 107.83 | ₹6.38 | +0.75% |
| ASTERDM.NS | ₹687.90 | +2.67% | 355.6B | 106.98 | ₹6.43 | +0.75% |
| NH.BO | ₹1,635.80 | +1.88% | 332.2B | 39.36 | ₹41.56 | +0.28% |
Stock Comparison
INDRAMEDCO.NS vs APOLLOHOSP.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, APOLLOHOSP.NS has a market cap of 1.1T. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while APOLLOHOSP.NS trades at ₹7,305.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas APOLLOHOSP.NS's P/E ratio is 58.30. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to APOLLOHOSP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check APOLLOHOSP.NS's competition here
INDRAMEDCO.NS vs APOLLOHOSP.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, APOLLOHOSP.BO has a market cap of 1.1T. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while APOLLOHOSP.BO trades at ₹7,305.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas APOLLOHOSP.BO's P/E ratio is 58.30. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to APOLLOHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check APOLLOHOSP.BO's competition here
INDRAMEDCO.NS vs MAXHEALTH.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MAXHEALTH.NS has a market cap of 933.1B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MAXHEALTH.NS trades at ₹958.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MAXHEALTH.NS's P/E ratio is 65.99. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to MAXHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MAXHEALTH.NS's competition here
INDRAMEDCO.NS vs MAXHEALTH.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MAXHEALTH.BO has a market cap of 932.4B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MAXHEALTH.BO trades at ₹958.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MAXHEALTH.BO's P/E ratio is 65.99. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to MAXHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MAXHEALTH.BO's competition here
INDRAMEDCO.NS vs FORTIS.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, FORTIS.NS has a market cap of 600.2B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while FORTIS.NS trades at ₹795.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas FORTIS.NS's P/E ratio is 62.50. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to FORTIS.NS's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to FORTIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check FORTIS.NS's competition here
INDRAMEDCO.NS vs FORTIS.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, FORTIS.BO has a market cap of 599.9B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while FORTIS.BO trades at ₹794.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas FORTIS.BO's P/E ratio is 62.51. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to FORTIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check FORTIS.BO's competition here
INDRAMEDCO.NS vs ASTERDM.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, ASTERDM.BO has a market cap of 355.6B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while ASTERDM.BO trades at ₹687.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas ASTERDM.BO's P/E ratio is 107.83. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to ASTERDM.BO's ROE of +0.09%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to ASTERDM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check ASTERDM.BO's competition here
INDRAMEDCO.NS vs ASTERDM.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, ASTERDM.NS has a market cap of 355.6B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while ASTERDM.NS trades at ₹687.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas ASTERDM.NS's P/E ratio is 106.98. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to ASTERDM.NS's ROE of +0.09%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to ASTERDM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check ASTERDM.NS's competition here
INDRAMEDCO.NS vs NH.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, NH.BO has a market cap of 332.2B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while NH.BO trades at ₹1,635.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas NH.BO's P/E ratio is 39.36. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to NH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check NH.BO's competition here
INDRAMEDCO.NS vs NH.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, NH.NS has a market cap of 332.1B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while NH.NS trades at ₹1,635.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas NH.NS's P/E ratio is 42.62. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to NH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check NH.NS's competition here
INDRAMEDCO.NS vs MEDANTA.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MEDANTA.BO has a market cap of 266B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MEDANTA.BO trades at ₹990.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MEDANTA.BO's P/E ratio is 51.73. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to MEDANTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MEDANTA.BO's competition here
INDRAMEDCO.NS vs MEDANTA.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MEDANTA.NS has a market cap of 265.9B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MEDANTA.NS trades at ₹989.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MEDANTA.NS's P/E ratio is 51.71. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to MEDANTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MEDANTA.NS's competition here
INDRAMEDCO.NS vs KIMS.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, KIMS.NS has a market cap of 250B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while KIMS.NS trades at ₹624.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas KIMS.NS's P/E ratio is 83.10. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to KIMS.NS's ROE of +0.13%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to KIMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check KIMS.NS's competition here
INDRAMEDCO.NS vs KIMS.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, KIMS.BO has a market cap of 249.9B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while KIMS.BO trades at ₹624.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas KIMS.BO's P/E ratio is 82.95. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to KIMS.BO's ROE of +0.13%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to KIMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check KIMS.BO's competition here
INDRAMEDCO.NS vs RAINBOW.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, RAINBOW.NS has a market cap of 119.4B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while RAINBOW.NS trades at ₹1,175.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas RAINBOW.NS's P/E ratio is 46.56. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to RAINBOW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check RAINBOW.NS's competition here
INDRAMEDCO.NS vs RAINBOW.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, RAINBOW.BO has a market cap of 119.3B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while RAINBOW.BO trades at ₹1,174.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas RAINBOW.BO's P/E ratio is 46.54. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to RAINBOW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check RAINBOW.BO's competition here
INDRAMEDCO.NS vs JLHL.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, JLHL.BO has a market cap of 81.9B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while JLHL.BO trades at ₹1,249.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas JLHL.BO's P/E ratio is 43.43. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to JLHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check JLHL.BO's competition here
INDRAMEDCO.NS vs JLHL.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, JLHL.NS has a market cap of 81.8B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while JLHL.NS trades at ₹1,246.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas JLHL.NS's P/E ratio is 43.25. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to JLHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check JLHL.NS's competition here
INDRAMEDCO.NS vs HCG.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, HCG.NS has a market cap of 79.9B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while HCG.NS trades at ₹535.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas HCG.NS's P/E ratio is 408.51. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to HCG.NS's ROE of +0.02%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to HCG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check HCG.NS's competition here
INDRAMEDCO.NS vs HCG.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, HCG.BO has a market cap of 79.9B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while HCG.BO trades at ₹535.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas HCG.BO's P/E ratio is 408.44. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to HCG.BO's ROE of +0.02%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to HCG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check HCG.BO's competition here
INDRAMEDCO.NS vs YATHARTH.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, YATHARTH.NS has a market cap of 64.2B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while YATHARTH.NS trades at ₹666.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas YATHARTH.NS's P/E ratio is 38.31. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to YATHARTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check YATHARTH.NS's competition here
INDRAMEDCO.NS vs YATHARTH.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, YATHARTH.BO has a market cap of 64.2B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while YATHARTH.BO trades at ₹665.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas YATHARTH.BO's P/E ratio is 38.25. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check YATHARTH.BO's competition here
INDRAMEDCO.NS vs KOVAI.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, KOVAI.BO has a market cap of 55.3B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while KOVAI.BO trades at ₹5,056.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas KOVAI.BO's P/E ratio is 23.47. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to KOVAI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check KOVAI.BO's competition here
INDRAMEDCO.NS vs INDRAMEDCO.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, INDRAMEDCO.BO has a market cap of 36.6B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while INDRAMEDCO.BO trades at ₹398.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas INDRAMEDCO.BO's P/E ratio is 19.98. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to INDRAMEDCO.BO's ROE of +0.31%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to INDRAMEDCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check INDRAMEDCO.BO's competition here
INDRAMEDCO.NS vs KOVAI.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, KOVAI.NS has a market cap of 35.3B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while KOVAI.NS trades at ₹2,581.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas KOVAI.NS's P/E ratio is 20.74. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to KOVAI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check KOVAI.NS's competition here
INDRAMEDCO.NS vs ARTEMISMED.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, ARTEMISMED.NS has a market cap of 35.1B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while ARTEMISMED.NS trades at ₹222.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas ARTEMISMED.NS's P/E ratio is 97.19. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to ARTEMISMED.NS's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check ARTEMISMED.NS's competition here
INDRAMEDCO.NS vs ARTEMISMED.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, ARTEMISMED.BO has a market cap of 35B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while ARTEMISMED.BO trades at ₹221.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to ARTEMISMED.BO's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to ARTEMISMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check ARTEMISMED.BO's competition here
INDRAMEDCO.NS vs DRAGARWQ.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, DRAGARWQ.BO has a market cap of 22.7B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while DRAGARWQ.BO trades at ₹4,700.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas DRAGARWQ.BO's P/E ratio is 31.85. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to DRAGARWQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check DRAGARWQ.BO's competition here
INDRAMEDCO.NS vs SHALBY.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, SHALBY.BO has a market cap of 15.1B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while SHALBY.BO trades at ₹140.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas SHALBY.BO's P/E ratio is 182.66. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to SHALBY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check SHALBY.BO's competition here
INDRAMEDCO.NS vs SHALBY.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, SHALBY.NS has a market cap of 15B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while SHALBY.NS trades at ₹139.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas SHALBY.NS's P/E ratio is 181.26. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to SHALBY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check SHALBY.NS's competition here
INDRAMEDCO.NS vs KMCSHIL.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, KMCSHIL.BO has a market cap of 13.3B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while KMCSHIL.BO trades at ₹81.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas KMCSHIL.BO's P/E ratio is 36.44. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to KMCSHIL.BO's ROE of +0.22%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to KMCSHIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check KMCSHIL.BO's competition here
INDRAMEDCO.NS vs MAXINDIA.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to MAXINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MAXINDIA.BO's competition here
INDRAMEDCO.NS vs MAXIND.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MAXIND.NS has a market cap of 7.4B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MAXIND.NS trades at ₹141.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MAXIND.NS's P/E ratio is -4.74. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MAXIND.NS's competition here
INDRAMEDCO.NS vs UNIHEALTH.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, UNIHEALTH.NS has a market cap of 5.9B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while UNIHEALTH.NS trades at ₹380.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas UNIHEALTH.NS's P/E ratio is 38.71. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to UNIHEALTH.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to UNIHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check UNIHEALTH.NS's competition here
INDRAMEDCO.NS vs ASARFI.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, ASARFI.BO has a market cap of 3.5B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while ASARFI.BO trades at ₹177.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas ASARFI.BO's P/E ratio is 21.30. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to ASARFI.BO's ROE of +0.14%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to ASARFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check ASARFI.BO's competition here
INDRAMEDCO.NS vs LOTUSEYE.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, LOTUSEYE.NS has a market cap of 2.1B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while LOTUSEYE.NS trades at ₹101.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas LOTUSEYE.NS's P/E ratio is 318.25. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to LOTUSEYE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check LOTUSEYE.NS's competition here
INDRAMEDCO.NS vs LOTUSEYE.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, LOTUSEYE.BO has a market cap of 2.1B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while LOTUSEYE.BO trades at ₹101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas LOTUSEYE.BO's P/E ratio is 317.50. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to LOTUSEYE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check LOTUSEYE.BO's competition here
INDRAMEDCO.NS vs LEHIL.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check LEHIL.BO's competition here
INDRAMEDCO.NS vs MADHAVBAUG.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MADHAVBAUG.NS has a market cap of 1.7B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MADHAVBAUG.NS trades at ₹164.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MADHAVBAUG.NS's P/E ratio is 21.24. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MADHAVBAUG.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to MADHAVBAUG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MADHAVBAUG.NS's competition here
INDRAMEDCO.NS vs AASHKA.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, AASHKA.BO has a market cap of 1.4B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while AASHKA.BO trades at ₹60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas AASHKA.BO's P/E ratio is 57.69. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to AASHKA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check AASHKA.BO's competition here
INDRAMEDCO.NS vs JSTL.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, JSTL.BO has a market cap of 1B. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while JSTL.BO trades at ₹63.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas JSTL.BO's P/E ratio is -49.94. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check JSTL.BO's competition here
INDRAMEDCO.NS vs MAITREYA.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MAITREYA.NS has a market cap of 999.5M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MAITREYA.NS trades at ₹184.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MAITREYA.NS's P/E ratio is 28.58. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MAITREYA.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to MAITREYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MAITREYA.NS's competition here
INDRAMEDCO.NS vs FORTISMLR.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, FORTISMLR.BO has a market cap of 854.4M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while FORTISMLR.BO trades at ₹45.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas FORTISMLR.BO's P/E ratio is 18.84. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to FORTISMLR.BO's ROE of +0.15%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to FORTISMLR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check FORTISMLR.BO's competition here
INDRAMEDCO.NS vs ASPIRA.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, ASPIRA.BO has a market cap of 606.5M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while ASPIRA.BO trades at ₹58.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas ASPIRA.BO's P/E ratio is 42.70. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to ASPIRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check ASPIRA.BO's competition here
INDRAMEDCO.NS vs SANGANI.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, SANGANI.NS has a market cap of 558M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while SANGANI.NS trades at ₹40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas SANGANI.NS's P/E ratio is 21.54. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to SANGANI.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to SANGANI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check SANGANI.NS's competition here
INDRAMEDCO.NS vs AATMAJ.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, AATMAJ.NS has a market cap of 463.3M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while AATMAJ.NS trades at ₹20.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas AATMAJ.NS's P/E ratio is 52.56. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to AATMAJ.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to AATMAJ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check AATMAJ.NS's competition here
INDRAMEDCO.NS vs NGIND.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, NGIND.BO has a market cap of 453.2M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while NGIND.BO trades at ₹135.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas NGIND.BO's P/E ratio is -32.75. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to NGIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check NGIND.BO's competition here
INDRAMEDCO.NS vs MEDINOV.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check MEDINOV.BO's competition here
INDRAMEDCO.NS vs SML.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, SML.BO has a market cap of 299.5M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while SML.BO trades at ₹70.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas SML.BO's P/E ratio is -15.00. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to SML.BO's ROE of -2.04%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to SML.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check SML.BO's competition here
INDRAMEDCO.NS vs TEJNAKSH.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, TEJNAKSH.BO has a market cap of 267.1M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while TEJNAKSH.BO trades at ₹13.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas TEJNAKSH.BO's P/E ratio is 19.34. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check TEJNAKSH.BO's competition here
INDRAMEDCO.NS vs KKSHL.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, KKSHL.BO has a market cap of 250.9M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while KKSHL.BO trades at ₹36.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas KKSHL.BO's P/E ratio is -24.40. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to KKSHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check KKSHL.BO's competition here
INDRAMEDCO.NS vs CMMHOSP.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, CMMHOSP.BO has a market cap of 246.3M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while CMMHOSP.BO trades at ₹32.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas CMMHOSP.BO's P/E ratio is -31.70. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to CMMHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check CMMHOSP.BO's competition here
INDRAMEDCO.NS vs NIDAN.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, NIDAN.NS has a market cap of 189M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while NIDAN.NS trades at ₹13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas NIDAN.NS's P/E ratio is 9.58. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to NIDAN.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to NIDAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check NIDAN.NS's competition here
INDRAMEDCO.NS vs FAMILYCARE.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, FAMILYCARE.BO has a market cap of 151.2M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while FAMILYCARE.BO trades at ₹2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas FAMILYCARE.BO's P/E ratio is -2.89. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check FAMILYCARE.BO's competition here
INDRAMEDCO.NS vs GLHRL.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, GLHRL.BO has a market cap of 150M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while GLHRL.BO trades at ₹14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas GLHRL.BO's P/E ratio is -6.35. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to GLHRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check GLHRL.BO's competition here
INDRAMEDCO.NS vs ZDHJERK.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, ZDHJERK.BO has a market cap of 107.8M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while ZDHJERK.BO trades at ₹26.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas ZDHJERK.BO's P/E ratio is 87.67. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to ZDHJERK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check ZDHJERK.BO's competition here
INDRAMEDCO.NS vs LOOKS.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, LOOKS.BO has a market cap of 66.2M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while LOOKS.BO trades at ₹6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas LOOKS.BO's P/E ratio is 31.50. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to LOOKS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check LOOKS.BO's competition here
INDRAMEDCO.NS vs GIANLIFE.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, GIANLIFE.BO has a market cap of 65M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while GIANLIFE.BO trades at ₹6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas GIANLIFE.BO's P/E ratio is -6.69. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, INDRAMEDCO.NS is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check GIANLIFE.BO's competition here
INDRAMEDCO.NS vs DLCL.BO Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, DLCL.BO has a market cap of 64.2M. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while DLCL.BO trades at ₹14.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas DLCL.BO's P/E ratio is 19.23. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to DLCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check DLCL.BO's competition here
INDRAMEDCO.NS vs NEPHROCARE-ST.NS Comparison April 2026
INDRAMEDCO.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDRAMEDCO.NS stands at 36.6B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, INDRAMEDCO.NS is priced at ₹399.70, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDRAMEDCO.NS currently has a P/E ratio of 20.03, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, INDRAMEDCO.NS's ROE is +0.31%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, INDRAMEDCO.NS is more volatile compared to NEPHROCARE-ST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDRAMEDCO.NS.Check NEPHROCARE-ST.NS's competition here